en · de · es · fr · pt
tb-500-notes.peptides4962.com › Wiki › Tb-500 Identity And Chemical Background — Complete Guide

Tb-500 Identity And Chemical Background — Complete Guide

By Editorial Desk · published 2026-01-25 · last reviewed 2026-03-14 · Wiki

Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-14. Where a claim depends on a specific study, the study is described rather than over-claimed.

TB-500 Identity and Chemical Background

Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.

Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.

Detection, Stability, and Regulatory Status

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.

Tb-500 at a glance

PropertyValueNotes
Physical formLyophilised powderSealed vial; reconstituted before laboratory use
AppearanceWhite to off-white solidVisual descriptor used on certificates of analysis
Solubility classWater-solubleDissolves in water and aqueous buffers
Reported mass, fragmentNear 889 DaValue depends on the stated sequence
Reported mass, parent proteinNear 4963 Da43-residue thymosin beta-4

Identity and Reported Background

Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

Related pages on this site

TB-500 Background and Identity

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

Reference notes

== Caring for human remains == Though there is great variety in human remains within museum collections as well as the ways in which they can be preserved, there are a number of best practices to be observed in the preventive care of these types of artifacts. Preventive conservation is the best method of preserving human remains in the long term, as active conservation work should be limited both by conservators' policy to interfere as little as possible and the beliefs of many indigenous tribes and groups who disapprove of altering human remains.

This regulates the reaction catalyzing fructose 2,6-bisphosphate (a potent activator of phosphofructokinase-1, the enzyme that is the primary regulatory step of glycolysis) by slowing the rate of its formation, thereby inhibiting the flux of the glycolysis pathway and allowing gluconeogenesis to predominate. This process is reversible in the absence of glucagon (and thus, the presence of insulin). Glucagon stimulation of PKA inactivates the glycolytic enzyme pyruvate kinase, inactivates glycogen synthase, and activates hormone-sensitive lipase, which catabolizes glycerides into glycerol and free fatty acid(s), in hepatocytes. Glucagon also inactivates acetyl-CoA carboxylase (ACC), which creates malonyl-CoA from acetyl-CoA, through cAMP-dependent and/or cAMP-independent kinases. Malonyl-CoA is a product formed by ACC during denovo synthesis and an allosteric inhibitor of carnitine palmitoyltransferase I (CPT1), a mitochondrial enzyme important for bringing fatty acids into the intermembrane space of the mitochondria for β-oxidation. Glucagon decreases malonyl-CoA through inhibition of acetyl-CoA carboxylase and through reduced glycolysis through its aforementioned reduction in Fructose 2,6-bisphosphate. Thus, reduction in malonyl-CoA is a common regulator for the increased fatty acid metabolism effects of glucagon.

The WPB placed penicillin under a wartime allocation system on 16 July 1943. All supplies were designated for use by the armed forces and the Public Health Service. Penicillin production in the United States ramped up from 800 million Oxford units in the first half of 1943 to 20 billion units in the second half. The US government built six production plants at a cost of $7.6 million (equivalent to $139 million in 2025). These were sold after the war to the companies that operated them for $3.4 million (equivalent to $56 million in 2025). Another sixteen plants were built by the private sector for $22.6 million (equivalent to $413 million in 2025), although $14.5 million (equivalent to $265 million in 2025) was approved for accelerated depreciation under which the cost could be written off in five years instead of the usual twelve to fifteen. US penicillin production rose from 21 billion units in 1943, to 1,663 billion units in 1944 and an estimated 6,852 billion units in 1945. By June 1944, Pfizer alone was producing 70 billion units per month. Monthly production dropped off after July 1945 due to a shortage of corn-steep liquor. The price offered by the CMR for a million units fell from $200 in 1943 (equivalent to $4,000 in 2025), which was below its manufacturing cost, to $6 in 1945 (equivalent to $107 in 2025). The chairman of the NRC committee on chemotherapy, Chester Keefer, was responsible for administering the equitable distribution of penicillin for civilian use on behalf of the CMR.

In 2017, to coincide with the opening of Little Caesars Arena, the company launched a slightly updated logo, which removed Caesar's chest hair, updated the wreath, and updated the toga to have hidden letters spelling "LC" for "Little Caesars". The company also started using the updated Caesar in its advertising, replacing the more cartoonish Caesar that had been used in ads since 1988.

== See also == Substituted methoxyphenethylamine 4-Substituted 2,5-dimethoxyphenethylamines (2Cs) 4-Substituted 2,5-dimethoxyamphetamines (DOx) 4-Substituted 2,5-dimethoxy-α-ethylphenethylamines (4Cs) List of miscellaneous 5-HT2A receptor agonists

Sources: en.wikipedia.org

Notes from published material

Working at the Royal Society in the 1660s, the physician Richard Lower began examining the effects of changes in blood volume on circulatory function and developed methods for cross-circulatory study in animals, obviating clotting by closed arteriovenous connections. The new instruments he was able to devise enabled him to perform the first reliably documented successful transfusion of blood in front of his distinguished colleagues from the Royal Society. According to Lower's account, "...towards the end of February 1665 [I] selected one dog of medium size, opened its jugular vein, and drew off blood, until its strength was nearly gone. Then, to make up for the great loss of this dog by the blood of a second, I introduced blood from the cervical artery of a fairly large mastiff, which had been fastened alongside the first, until this latter animal showed ... it was overfilled ... by the inflowing blood." After he "sewed up the jugular veins", the animal recovered "with no sign of discomfort or of displeasure". Lower had performed the first blood transfusion between animals. He was then "requested by the Honorable [Robert] Boyle ... to acquaint the Royal Society with the procedure for the whole experiment", which he did in December 1665 in the Society's Philosophical Transactions. The first blood transfusion from animal to human was administered by Jean-Baptiste Denys, eminent physician to King Louis XIV of France, on June 15, 1667. He transfused the blood of a sheep into a 15-year-old boy, who survived the transfusion.

cell physiology The study of the various biological activities and biochemical processes which sustain life inside cells, particularly (but not necessarily limited to) those related to metabolism and energy transfer, growth and reproduction, and the ordinary processes of the cell cycle.

Many social-democratic parties, particularly after the Cold War, adopted neoliberal economic policies, including austerity, deregulation, financialisation, free trade, privatisation and welfare reforms such as workfare, experiencing a drastic decline in the 2010s after their successes in the 1990s and 2000s in a phenomenon known as Pasokification. As monetarists and neoliberals attacked social welfare systems as impediments to private entrepreneurship, prominent social-democratic parties abandoned their pursuit of moderate socialism in favour of economic liberalism. This resulted in the rise of more left-wing and democratic socialist parties that rejected neoliberalism and the Third Way. In the United Kingdom, prominent democratic socialists within the Labour Party such as Michael Foot and Tony Benn put forward democratic socialism into an actionable manifesto during the 1970s and 1980s, but this was voted overwhelmingly against in the 1983 general election after Margaret Thatcher's victory in the Falklands War and the manifesto was referred to as "the longest suicide note in history." By the 1980s, with the rise of conservative neoliberal politicians such as Ronald Reagan in the United States, Margaret Thatcher in Britain, Brian Mulroney in Canada and Augusto Pinochet in Chile, the Western welfare state was attacked from within, but state support for the corporate sector was maintained.

The structure of histatin is unique depending on whether the protein of interest is histatin 1, 3 or 5. Nonetheless, histatins mainly possess a cationic (positive) charge due to the primary structure consisting mostly of basic amino acids. An amino acid that is crucial to histatin's function is histidine. Studies show that the removal of histidine (especially in histatin 5) resulted in reduction of antifungal activity.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.

Why do product listings show different sequences?

Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.

What is the reported molecular mass?

The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.

How is the peptide detected in samples?

The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.

Network